Prevention of stroke in patients with atrial fibrillation: current strategies and future direc- tions. Eur Heart J. 2007;10:H4 10. S4.1.1-24. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005.:CD001927. S4.1.1-25. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857 67. S4.1.1-26. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662 8. S4.1.1-27. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134:24 36. S4.1.1-28. Khoury T, Ayman AR, Cohen J, et al. The complex role of anticoagu- lation in cirrhosis: an updated review of where we are and where we are going. Digestion. 2016;93:149 59. S4.1.1-29. Bonde AN, Lip GYH, Kamper A-L, et al. Net clinical benefit of anti- thrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471 82. S4.1.1-30. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibril- lation in the United States. Circulation. 2018;138:1519 29. S4.1.1-31. Andersson T, Magnuson A, Bryngelsson I-L, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortal- ity in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol. 2014;177:91 9. S4.1.1-32. Fang MC, Singer DE, Chang Y, et al. 